Fieldpoint Private Securities’s Emergent Biosolutions EBS Stock Holding History

Fieldpoint Private Securities’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Sell	40 -25	-38%	-$854	﹤0.01%	1324
2022 Q1	$3K	Sell	65 -220	-77%	-$9.7K	﹤0.01%	1393
2021 Q4	$12K	Buy	285 +120	+73%	+$5.43K	﹤0.01%	1026
2021 Q3	$8K	Hold	165	–	–	﹤0.01%	1107
2021 Q2	$10K	Buy	165 +20	+14%	+$1.28K	﹤0.01%	1013
2021 Q1	$13K	Hold	145	–	–	﹤0.01%	913
2020 Q4	$13K	Buy	+145	New	+$13.3K	﹤0.01%	814

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fieldpoint Private Securities's EBS Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Emergent Biosolutions (EBS) stake by 38% in Q2 2022, selling an estimated $854 and leaving 40 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Fieldpoint Private Securities first reported a position in EBS in Q4 2020 and has held it in 7 quarters since. The position peaked at $13K in Q1 2021. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

Fieldpoint Private Securities held 40 shares of Emergent Biosolutions worth $1K as of Q2 2022.
Fieldpoint Private Securities sold 25 Emergent Biosolutions shares in Q2 2022, an estimated $854.
Emergent Biosolutions made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1324 holding.
Fieldpoint Private Securities first reported a position in Emergent Biosolutions in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Emergent Biosolutions position peaked at $13K in Q1 2021.
231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.